Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protocol I8K-MC-JPDA – LY3337641 in Rheumatoid Arthritis
2015-003289-97Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of poseltinib in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Safety and tolerability of LY3337641. Started Aug 2016; status: completed.
02
Drugs
poseltinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-003289-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003289-97.